Abbott Laboratories (ABT)

NYSE · Medical Devices

106.20
+1.63 (+1.56%)
Updated Oct 31, 6:23 PM ET
AI Rating
Strong Buy
Overall Score
79
Trend
77
Momentum
79
Risk
83

Scores are generated from technical indicators for educational purposes and are not a recommendation to buy or sell.

Price history

Daily closes and volume
Oct 14, 2025 260 sessions Oct 26, 2026

AI Analysis

Abbott Laboratories is trading at $106.17, up 1.53% on the session. The 50 day average sits at $105.04 and the 200 day at $102.11, which puts the stock in a uptrend. RSI is at 57.1, which reads as strong, and MACD is bullish crossover. Volume is below average.

The nearest support is around $100.33 with resistance near $106.35, so that band frames the current range. Average daily movement is roughly $2.83, or about 2.7% of the share price, which is what any stop placement has to allow for. The overall health score of 71 out of 100 combines a trend score of 57, momentum of 79 and a risk score of 83.

Technical indicators

RSI (14)
57.1
strong
MACD
0.141
bullish crossover
SMA 20
101.21
SMA 50
105.04
SMA 200
102.11
uptrend
ATR (14)
2.83
avg daily range
Support
100.33
Resistance
106.35
Volume vs 20d
0.77x
below average
Volatility
23.9%
annualised
1 month
+3.54%
3 months
-2.23%

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

Company website

Stay Ahead of the Market

Get daily AI insights, market updates, and trade opportunities delivered to your inbox.